menu
    • menu
    [{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series A Financing","leadProduct":"Sirolimus","moa":"||mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Advanced NanoTherapies

    Menu

    Advanced NanoTherapies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Advanced NanoTherapies

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed

                            Advanced NanoTherapies

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus,Paclitaxel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $4.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Advanced NanoTherapies (ANT) Secures $4M Strategic Investment to Accelerate Clinical Development of SirPlux Du...

                            Details : The financing will be used to accelerate clinical development of next-generation SirPlux duo drug-coated balloon (DCB) which combines the synergistic power of sirolimus and paclitaxel to create a next-generation, front-line therapy for treating de novo c...

                            Product Name : SirPlux Duo DCB

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            August 22, 2023

                            Lead Product(s) : Sirolimus,Paclitaxel

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $4.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Advanced NanoTherapies

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed

                            Advanced NanoTherapies

                            U.S.A arrow
                            EASL Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel,Sirolimus

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $7.2 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing

                            Details : Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo (paclitaxel and sirolimus) drug-coated balloon (DCB) in de-novo coronary artery disease (CAD) lesions.

                            Product Name : SirPlux Duo

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            June 28, 2022

                            Lead Product(s) : Paclitaxel,Sirolimus

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $7.2 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth